HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRN Ends Funding For Industry Self-Regulation Program Focused On Supplement Advertising

Executive Summary

The trade group ends funding for National Advertising Division program launched in 2006 for increased focus on monitoring supplement claims, reviewing 360 in total. Separately, NAD launches an expedited challenge process aiming to conclude reviews in 20 business days.

You may also be interested in...



NAD’s Laura Brett Looks At 2024: ‘Clean Beauty,’ Influencers, Health Claims, Dark Patterns And AI

Brett discusses the BBB National Programs division’s plans for beauty and wellness activities in the new year, the ongoing challenge of getting influencers and brands to disclose material relationships, the FTC’s Health Products Compliance Guidance, and more in a 28 November interview with HBW Insight.

Industry Self-Regulation Reviews Show Influencers Aren’t Ad Claim Compliance Experts

Sustainability claims are growing as targets of reviews by BBB National Programs investigative divisions, which also anticipate more ad violations from online dark patterns in 2022.

NAD Simplifies, Lowers Fees For Disclosure Challenges In SWIFT Ad Claim Reviews

National Advertising Division streamlined the process for submitting SWIFT challenges about disclosure claims and lowered the filing fee for the challenges. Growing use of testimonials, “influencer” marketing prompted change.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel